By Wolfgang Hackl, CEO, OncoGenomX Inc., Allschwil, Switzerland

In women’s health, “free” digital tools occupy an especially sensitive space. Period trackers, fertility apps, pregnancy platforms, menopause programs, pelvic-floor wearables, contraception reminders, mental-health chatbots and symptom diaries have become essential resources for millions worldwide. For many, these tools fill longstanding gaps in clinical care, offering information, monitoring and community.

Yet women’s health data are uniquely intimate, politically vulnerable and commercially valuable. The same apps that help a woman identify a fertility window or track post-partum mood changes may also collect sexual history, location, device IDs, hormonal patterns, and behavioral clues that can be monetized or repurposed – sometimes without meaningful transparency.

The core ethical question is urgent: When does the data exchange that underpins “free” women’s health tools empower individuals, and when does it exploit them?

Across research and policy commentary, the fault lines remain the same – transparency, proportionality, control, fair value sharing, and protection from harm – but their stakes are heightened in women’s health.

The high-risk profile of women’s health data

The sensitivity of women’s health data is not abstract. It becomes dangerous in real-world contexts:

• Reproductive rights volatility – In jurisdictions with restrictive reproductive laws, menstrual cycle data, geolocation patterns around clinics, search histories and communication logs can be weaponized.
• Stigma and discrimination – Data related to miscarriage, abortion, infertility, menopause symptoms, mental health, sexual function or domestic violence can lead to insurance denial, unfair pricing, employment impacts or social vulnerability.
• Relationship and safety risk – Some apps collect or expose data that partners or third parties could misuse, from mood logs to location traces.
• Commercial targeting – Women are historically targeted with exploitative advertising around fertility supplements, weight loss, anti-aging and alternative therapies, often amplified by intimate behavioral data.

These risks transform the ethics of “free.” When a tool’s business model depends on collecting sensitive reproductive or behavioral attributes at scale, the user is no longer the beneficiary – the user is the product.

What women expect when sharing health data

Studies consistently show broad support among women for sharing data when it drives tangible health benefits—research, better care pathways, early diagnosis, or community insights. Trust collapses when data are:

• shared with advertisers, data brokers or insurers
• used for profiling, risk scoring or targeted pricing
• stored indefinitely or without clarity
• accessible to third parties unknown to the user

Women expect three things above all:

1. Radical transparency

Not euphemisms, not hidden trackers, not 30-page terms. Women want to know who sees what, why and how it will be protected.

2. Meaningful agency

Granular control – “yes” to sharing anonymized cycle data for research, “no” to targeted ads; “yes” to contributing to public-good datasets, “no” to third-party data inference.

3. Safety guarantees

Technical and legal safeguards that explicitly prohibit uses exposing women to legal, financial, physical or psychological risk.

Women’s health is not a sandbox for broad, open-ended data collection. When platforms request permissions unrelated to their core health function – photos, contacts, continuous location, device fingerprinting – alarm bells ring.

Exploitation patterns in “free” women’s health tools

Technical audits of menstrual and fertility apps show that many collect extraordinarily detailed data: cycle length, symptoms, sexual activity, pregnancy intentions, test results, mood logs, sleep, stress, location, device IDs, email metadata, and “other information.” Some share with dozens of third parties.

The exploitation signals are increasingly well understood:

• Opaque data pipelines to marketers, analytics firms and profiling engines
• Unbounded storage of sensitive reproductive histories
• Engagement-driven design that nudges users toward disclosing more
• Commercial re-use of intimate behavioral patterns unrelated to health
• Minimal or performative governance despite high-risk categories

When a woman logs cramps or sexual activity, the ethical baseline is higher than in general wellness apps. The potential harms – legal, social, relational – are uniquely gendered and often irreversible.

Value capture and the “women pay twice” problem

Women’s health technologies have become a multi-billion-dollar market. But the value chain often flows upward, not back to the users:

1. Women supply intimate, high-granularity data – Immense value for R&D, precision marketing, and investor storytelling.
2. Companies monetize the insights – Through partnerships, advertising, risk scoring or AI model development.
3. Women then purchase the resulting products – Including paid upgrades, supplements, or premium diagnostics whose innovation was subsidized by their data.

Without mechanisms that guarantee affordability, open reporting or reinvestment into women’s health services, the model becomes extractive. Women contribute the raw material, then buy back the finished product at retail price.

Pathways to acceptable – and truly empowering – data use

Responsible data practice in women’s health requires stricter standards than generic “digital health ethics.” The following markers – derived from current scholarship—are especially critical in women’s health contexts:

1. Purpose-bound data practices

Tools should collect only what is strictly necessary for the health purpose. Fertility predictions do not require contact lists or persistent location tracking.

2. Prohibitions on harmful secondary uses

Contracts and code must explicitly block:

• insurance scoring
• law enforcement access without due process
• targeted advertising linked to reproductive data
• cross-platform tracking
• sale to data brokers

3. High-security architecture

Women’s health data should be treated like genomic or mental health data:

• encryption at rest and in transit
• zero-trust design
• independent security audits
• strict third-party access regimes

4. Governance designed for vulnerable contexts

Oversight bodies should include women’s health experts, legal scholars, and patient advocates, reviewing not just privacy compliance but real-world harm potential.

5. Fair value and reciprocity

If population-level reproductive or maternal health data fuel AI models, companies should commit to:

• affordability of products derived from those models
• investment in community health infrastructure
• transparency in data-driven improvements

This is not charity. It is ethical reciprocity.

The way forward: trust as a differentiator

Women’s health is evolving from niche to mainstream. With this visibility comes responsibility. Investors and innovators who treat data stewardship as a strategic asset – not a compliance hurdle—will define the next era of digital women’s health.

The future belongs to tools that:

• put safety ahead of scale
• align business models with women’s interests
• eliminate dark patterns
• prove that “free” does not mean “exploitative”
• create value with, not from, women

Ultimately, the line between acceptable data use and exploitation is shaped by one question:

Does this tool treat women as partners—or as data sources?

The companies that choose the former will earn the trust that defines the next generation of global women’s health innovation.